Noviocell BV
Oss · Founded 2015
About Noviocell BV
Noviocell BV is an innovative biotech company focusing on the development of a synthetic solution for 3D cell culturing for medicinal use. Noviocell will build upon its proprietary polyisocyanopeptide (PIC) hydrogel technology and develop them into easy-to-use solutions for biomedical researchers, biotech and pharma industry and clinicians. The PIC hydrogels are based on breakthrough research from the internationally highly rated Institute for Molecules and Materials at Radboud University, which has resulted in high-impact publications (Nature, Nature Material and Nature communications). The potential of 3D cell culturing is evident: never before have we been able to assess the complexity of (human) biology in such a detailed manner. Recent highlights include brain, liver and disease-specific organoids (which especially have shown tremendous value in combination with gene editing technology such as CRISPR/CAS). These will contribute to our understanding of health and disease as well as identification of new therapeutic targets and biomarkers. But to fully leverage the potential of 3D cell culturing it is necessary to address three key bottlenecks: robustness, scalability and clinical use.
Company Facts
- Founded: 2015
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $79.9K
- Last round: Grant (Jun 2016)
- Website: noviocell.com
- Phone: +31 6 46155064
Canonical: https://fsome.com/organization/noviocell-bv-8264530 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.